Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses

Area of Science:

• Oncology
• Dermatology
• Surgical Oncology

Background:

• Dermatofibrosarcoma protuberans (DFSP) is a rare, low-grade soft-tissue malignancy.
• DFSP frequently recurs locally and can spread widely, complicating surgical removal.
• Surgical excision of DFSP can lead to disfigurement and functional impairment.

Purpose of the Study:

• To evaluate the efficacy of neoadjuvant imatinib mesylate in reducing tumor size for DFSP.
• To assess the impact of neoadjuvant imatinib on surgical morbidity in DFSP patients.
• To inform patient selection and risk-benefit analysis for neoadjuvant imatinib therapy.

Main Methods:

• Review of recent cases utilizing neoadjuvant imatinib mesylate therapy for DFSP.
• Assessment of tumor size reduction prior to surgical excision.
• Evaluation of surgical morbidity and patient outcomes post-neoadjuvant therapy.

Main Results:

• Neoadjuvant imatinib mesylate therapy demonstrated a reduction in preoperative tumor size for DFSP.
• This approach lessened surgical morbidity associated with DFSP removal.
• Imatinib has shown benefit as adjuvant therapy for unresectable, recurrent, or metastatic DFSP.

Conclusions:

• Neoadjuvant imatinib mesylate is a potential strategy to improve surgical outcomes for DFSP.
• Careful patient selection and risk-benefit assessment are crucial for this treatment approach.
• Further research may elucidate optimal use of imatinib in the neoadjuvant setting for DFSP.